Publications

  1. Gostissa M, Schwer B, Chang A, Dong J, Meyers RM, Marecki GT, Choi VW, Chiarle R, Zarrin AA, Alt FW. IgH class switching exploits a general property of two DNA breaks to be joined in cis over long chromosomal distances. Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2644-9.
  2. Semrau S, Crosetto N, Bienko M, Boni M, Bernasconi P, Chiarle R*, van Oudenaarden A*. FuseFISH: Robust Detection of Transcribed Gene Fusions in Single Cells. Cell Rep. 2014 Jan 16;6(1):18-23. *Corresponding Authors.
  3. Chiarle R. Translocations in normal B cells and cancers: insights from new technical approaches. Adv Immunol. 2013;117:39-71.
  4. Crosetto N, Mitra A, Silva MJ, Bienko M, Dojer N, Wang Q, Karaca E, Chiarle R, Skrzypczak M, Ginalski K, Pasero P, Rowicka M, Dikic I. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nature Methods. 2013 Apr;10(4):361-5.
  5. Duan S, Cermak L, Pagan J, Rossi M, Martinengo C, Francia di Celle P, Chapuy B, Shipp M, Chiarle R*, and Pagano M*. FBXO11 targets BCL6 for degradation and is inactivated in Diffuse Large B-Cell Lymphomas. Nature 2012 Jan 5;481(7379):90-3. *Corresponding Authors.
  6. Chiarle R, Zhang Y, Frock RL, Lewis SM, Molinie B, Ho Y, Myers DR, Choi VW, Compagno M, Malkin DJ, Neuberg D, Monti S, Giallourakis CC, Gostissa M, and Alt FW. Genome-Wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells. Cell 2011 Sep 30;147(1):107-19. Highlighted on the Cell cover and in Cell 2011 Sep 30;147(1):20-2 and in Nature Review Genetics 2011 Nov;12(11):741.
  7. Gostissa M, Alt FW, Chiarle R. Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Annual Review Immunol 2011 Apr 23;29:319-50.
  8. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Review Cancer 2008 Jan;8(1):11-23. Highlighted on the Nat Rev Cancer cover.
  9. Chiarle R, Martinengo C, Mastini C, Ambrogio C, D’Escamard V, Forni G, Inghirami G. Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination. Nature Medicine 2008 Jun;14(6):676-80.
  10. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamò A, Raz R, Karras J, Levy DE , Inghirami G. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Medicine 2005;11(6): 623-629. Highlighted in Nature Medicine 2005 Jun;11(6):595-6.

       For a complete listing of publications, click here.